skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Characterization of (/sup 3/H)leukotriene D4 binding sites in guinea-pig ventricular myocardium

Journal Article · · J. Pharmacol. Exp. Ther.; (United States)
OSTI ID:5253918

(/sup 3/H)Leukotriene (LT) D4 was used to identify specific LTD4 binding sites in guinea-pig ventricular myocardial membranes. High-performance liquid chromatography analyses indicated that, in the presence of the gamma-glutamyl transpeptidase inhibitor L-serine-borate (80 mM), less than 3% of membrane-bound (/sup 3/H)LTD4 was converted to (/sup 3/H)LTC4 or (/sup 3/H)LTE4 at 30 degrees C. The specific (/sup 3/H) LTD4 binding, assayed in the presence of 80 mM L-serine-borate, reached a stable steady state within 45 min at 30 degrees C (pH 7.5). A monophasic Scatchard plot of saturation binding data yielded an apparent dissociation constant (Kd) of 3.4 +/- 2.1 nM and a maximum number of binding sites of 850 +/- 91 fmol/mg of protein. Competition binding studies with (/sup 3/H)LTD4, synthetic 5S, 6R-LTD4 (LTD4) and its diastereoisomer 5R,6S-LTD4, LTE4, LTC4 and the putative LT antagonists FPL 55712, 4R-hydroxy-5S-1-cysteinylglycine-6Z-nonadecanoic acid (2-nor-LTD1) and SKF 88046 demonstrated a potency order of LTD4 greater than LTE4 greater than LTC4 greater than 5R,6S-LTD4 much greater than 2-nor-LTD1. FPL 55712 and SKF 88046 were ineffective in displacing the specific (/sup 3/H)LTD4 binding. Pretreatment of the heart membranes with the sulfhydryl reducing reagent dithiothreitol decreased the specific (/sup 3/H)LTD4 binding in a concentration-dependent manner. Scatchard analyses of saturation isotherms indicated that 0.3 mM dithiothreitol pretreatment of heart membranes decreased the maximum number of binding sites of the (/sup 3/H)LTD4 binding to 368 +/- 61 fmol/mg of protein with minimal effects on the apparent Kd.

Research Organization:
Smith Kline and French Labs., Philadelphia, PA
OSTI ID:
5253918
Journal Information:
J. Pharmacol. Exp. Ther.; (United States), Vol. 3
Country of Publication:
United States
Language:
English